Alzamend Neuro, Inc. (ALZN)
Nasdaq · Healthcare · Biotechnology
$1.41+2.17%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $6.8M
- 52-week range
- $0.84 – $2.68
- 52-week change
- −44.98%
- EPS (trailing)
- −$2.30
Fiscal year to Apr 2026
- Net income
- −$8.8M
- Diluted EPS
- −$2.63
From the company’s annual report on SEC EDGAR.
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Headquarters: Atlanta, United States · 4 employees · alzamend.com